Markers of inflammation and hemodynamic measurements in obesity: Copenhagen City heart study

American Journal of Hypertension

Volumn 22, Issue 4, 2009, Pages 451-456

  Asferg, Camilla ^a   Jensen, Jan S ^b,c   Marott, Jacob L ^a   Appleyard, Merete ^a   Møgelvang, Rasmus ^b   Jensen, Gorm B ^a,c   Jeppesen, Jørgen ^a,c  

^a Mental Health Services CPH   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; MALE; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; DENMARK; FEMALE; FIBRINOGEN; HEMODYNAMICS; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; OBESITY;

EID: 62849107511     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.1     Document Type: Article

References (37)

1. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 5:152-158.
2. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19:857-861.
3. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22:1668-1673.
4. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, Park JR, Kim SW. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16:429-433.
5. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
6. Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R, Tuomainen TP, Salonen R, Salonen JT. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44:859-865.
7. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino RB Jr, Herrington DM. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005; 46:1869-1874.
8. Davey SG, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day IN, Ebrahim S. Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25:1051-1056.
9. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166:345-349.
10. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, Jacques PF, Meigs JB, Rifai N, Selhub J, Robins SJ, Newton-Cheh C, Vasan RS. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007; 49:432-438.
11. Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 2007; 49:304-310.
12. Gilardini L, Parati G, Sartorio A, Mazzilli G, Pontiggia B, Invitti C. Sympathoadrenergic and metabolic factors are involved in ambulatory blood pressure rise in childhood obesity. J Hum Hypertens 2008; 22:75-82.
13. Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de LJ. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population-II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost 1985; 54:721-723.
14. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258:1183-1186.
15. Lowe GD, Wood DA, Douglas JT, Riemersma RA, Macintyre CC, Takase T, Tuddenham EG, Forbes CD, Elton RA, Oliver MF. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost 1991; 65:339-343.
16. Smith WC, Lowe GD, Lee AJ, Tunstall-Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens 1992; 10:467-472.
17. Yang XC, Jing TY, Resnick LM, Phillips GB. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993; 13:467-471.
18. Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69:338-342.
19. Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J 1993; 14:597-601.
20. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47:513-524.
21. Green D, Ruth KJ, Folsom AR, Liu K. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb 1994; 14:686-693.
22. Dotevall A, Johansson S, Wilhelmsen L. Association between fibrinogen and other risk factors for cardiovascular disease in men and women. Results from the Goteborg MONICA survey 1985. Ann Epidemiol 1994; 4:369-374.
23. Sharp DS, Abbott RD, Burchfiel CM, Rodriguez BL, Tracy RP, Yano K, Curb JD. Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. Arterioscler Thromb Vasc Biol 1996; 16:262-268.
24. Sato S, Iso H, Naito Y, Kiyama M, Kitamura A, Iida M, Shimamoto T, Komachi Y. Plasma fibrinogen and its correlates in urban Japanese men. Int J Epidemiol 1996; 25:521-527.
25. Lemne C, De FU. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996; 26:692-697.
26. Folsom AR, Peacock JM, Nieto FJ, Rosamond WD, Eigenbrodt ML, Davis CE, Wu KK. Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens 1998; 16:1579-1583.
27. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101:264-269.
28. Shankar A, Wang JJ, Rochtchina E, Mitchell P. Positive association between plasma fibrinogen level and incident hypertension among men: population-based cohort study. Hypertension 2006; 48:1043-1049.
29. Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003; 290:3000-3002.
30. Eldrup N, Sillesen H, Prescott E, Nordestgaard BG. Ankle brachial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. Eur Heart J 2006; 27:316-322.
31. Appleyard M, Hansen AT, Schnohr P, Jensen G, Nyboe J. The Copenhagen City Heart Study. A book of tables with data from the first examination (1976-78) and a five-year follow-up (1981-83). Scand J Soc Med 1989; 170:1-160.
32. Schnohr P, Jensen G, Lange GP, Scharling H, Appleyard M. The Copenhagen City Heart Study. Tables with data from the third examination 1991-94. Eur Heart J 2001; 3:1-83.
33. López-Jaramillo P, Herrera E, Garcia RG, Camacho PA, Castillo VR. Interrelationships between body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population. Am J Hypertens 2008; 21:527-532.
34. Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, Nasir K. Markers of inflammation and coronary artery calcification: A systematic review. Atherosclerosis 2008; e-pub ahead of print 13 May 2008.
35. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
36. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004; 25:363-370.
37. Kannel WB. Framingham Study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995; 18:181-196.